Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merus N.V. - Common Shares
(NQ:
MRUS
)
52.66
+0.06 (+0.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merus N.V. - Common Shares
< Previous
1
2
3
Next >
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
June 04, 2025
Via
Benzinga
e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio?
June 01, 2025
11 mid-cap stocks soared last week, including LZ Technology, Centrus Energy, e.l.f Beauty, Merus, Oklo, NuScale Power, Informatica, BRP, Box, Joby Aviation, and C3.ai.
Via
Benzinga
D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?
May 25, 2025
Top mid-cap stocks gained up to 53.47% in the last week, including QBTS, RGC, AAP, MRUS, OKLO, SBSW, and BGM. Are they in your portfolio?
Via
Benzinga
Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On?
May 23, 2025
Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab...
Via
Benzinga
What's Going On With Merus Stock Monday?
January 13, 2025
Merus announced a research collaboration and license agreement with Biohaven.
Via
Benzinga
Expert Ratings for Merus
November 28, 2023
Via
Benzinga
Let's take a look at the stocks that are in motion in today's session.
May 23, 2025
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled
May 23, 2025
BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.
Via
Stocktwits
Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday
May 23, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
May 23, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
May 23, 2025
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
Via
Investor's Business Daily
Discover the top movers in Friday's pre-market session.
May 23, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Merus Shares Are Up Today: What's Going On?
February 18, 2025
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for...
Via
Benzinga
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
February 13, 2025
Via
Benzinga
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
January 10, 2025
Via
Benzinga
Merus Scores Its First FDA Approval For Lung Cancer Drug
December 05, 2024
FDA approves Merus' Bizengri as the first treatment for advanced NRG1 fusion-positive cancers. U.S. peak sales are estimated at $16.5 million.
Via
Benzinga
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'
December 05, 2024
Jim Cramer called Allison Transmission a "storied company... terrific. It does great."
Via
Benzinga
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
December 02, 2024
Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key focus for analysts.
Via
Benzinga
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
December 02, 2024
Via
Benzinga
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
November 21, 2024
Via
Benzinga
MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024
August 01, 2024
MRUS stock results show that Merus missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
Crude Oil Rises 1%; Verastem Shares Slide
May 24, 2024
Via
Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
May 24, 2024
Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with...
Via
Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
May 24, 2024
Via
Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
May 24, 2024
The company passed investors' bar for success in a study of a head-and-neck cancer treatment.
Via
Investor's Business Daily
Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
May 24, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 24, 2024
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!
Via
InvestorPlace
MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
MRUS stock results show that Merus beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.